Lenvatinib Biogaran

Lenvatinib, the active ingredient in Lenvatinib Biogaran, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It targets several advanced solid tumours by inhibiting angiogenic and proliferative signalling pathways in adult patients with documented efficacy in clinical trials.

GNH USA supplies Lenvatinib Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. Customers benefit from reliable lead times and comprehensive technical documentation.

Lenvatinib is indicated for solid tumours that depend on angiogenesis and growth‑factor signalling.

- Differentiated thyroid cancer: improves progression‑free survival in patients with radioactive‑iodine‑refractory disease. - Hepatocellular carcinoma: used in combination with atezolizumab for advanced disease. - Renal cell carcinoma: provides an oral option for metastatic clear‑cell RCC after prior therapy. - Endometrial cancer: approved for patients with advanced or recurrent disease not amenable to surgery.

Lenvatinib may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Hypertension - Diarrhea - Fatigue - Nausea

Serious or Rare Side Effects: - Hepatic failure - Severe hemorrhage - Fistula formation

When prescribing Lenvatinib, clinicians should observe several safety measures to minimise risk.

- Monitor blood pressure: check weekly and manage hypertension promptly. - Assess liver function: perform baseline and periodic LFTs. - Evaluate thyroid function: monitor TSH levels due to possible hypothyroidism. - Watch for bleeding: avoid concomitant use with anticoagulants unless necessary. - Avoid in patients with uncontrolled cardiovascular disease: consider alternative therapy. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Lenvatinib interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticoagulants and high‑dose aspirin: increase risk of severe bleeding.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: dose adjustments may be required due to blood‑pressure changes. - Diuretics: monitor electrolytes and renal function. - Other tyrosine‑kinase inhibitors: combined use may enhance toxicity.